Skip to main content

December 2015 Vol 8, No 9

David B. Nash, MD, MBA

Letters to the Editor

Correspondence: Cost of Treatment for Relapsed/Refractory Multiple Myeloma

Business, Original Research

Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors

Lisa M. Bloudek, PharmD, MS, Dinara Makenbaeva, MD, MBA, Michael Eaddy, PharmD, PhD

Stakeholder Perspective

Generic Imatinib: Can It Provide Significant Cost Relief for Patients?

by Gary Branning, MBA

The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice

Norman E. Lepor, MD, Dean J. Kereiakes, MD

Employers Engaged in Benefit Design Innovation: Long-Term Trends in a 2015 National Survey

Cheryl Larson, F. Randy Vogenberg, PhD, FASHP

Clinical, Original Research

Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis

Joseph Tkacz, MS, Michael P. Ingham, MSc, Brenna L. Brady, PhD, Roxanne Meyer, PharmD, Charles Ruetsch, PhD

Stakeholder Perspective

You Cannot Manage What You Cannot Measure

by Sharon Glave Frazee, PhD, MPH

Results 1 - 6 of 6